Judith Li Net Worth

Judith Li biography

Judith Li serves as Independent Director of the Company. Ms. Li has served as a member of our board of directors since September 2017. Ms. Li has served as a partner at Lilly Asia Ventures, or LAV, which is based in Hong Kong and Shanghai and focuses on early and growth stage investments across biopharmaceuticals, medical devices, and diagnostics both domestically and cross-border, since 2013. Ms. Li currently serves on the boards of directors of NextCure, Inc., a publicly traded biopharmaceutical company, as well as several of LAV’s private portfolio companies, including Fortis Therapeutics, Inhibrx, Inc., E-Scape Bio and TMunity Therapeutics. From April 2014 to October 2017, she served on the board of Crown BioScience Inc., a biotechnology company which was publicly listed on the Taiwan Stock Exchange until it was acquired in December 2017. Previously, Ms. Li served as a senior business analyst at McKinsey & Company, worked in hospital administration at Partners Healthcare, and co-founded an interventional nephrology medical device venture. Judith holds a B.A. in biology from Harvard and an M.B.A. from Harvard Business School.

What is the salary of Judith Li?

As the Independent Director of Gritstone Bio Inc, the total compensation of Judith Li at Gritstone Bio Inc is $104,949. There are 10 executives at Gritstone Bio Inc getting paid more, with Andrew Allen having the highest compensation of $2,187,440.

How old is Judith Li?

Judith Li is 36, she's been the Independent Director of Gritstone Bio Inc since 2017. There are 19 older and no younger executives at Gritstone Bio Inc. The oldest executive at Gritstone Bio Inc is Alan C. Mendelson J.D., 71, who is the Sec..

What's Judith Li's mailing address?

Judith's mailing address filed with the SEC is C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE, CA, 94608.

Insiders trading at Gritstone Bio Inc

Over the last 6 years, insiders at Gritstone Bio Inc have traded over $277,077 worth of Gritstone Bio Inc stock and bought 2,026,375 units worth $15,022,790 . The most active insiders traders include Group, Llc Green Jeremy Red..., Peter Svennilson e Thomas Woiwode. On average, Gritstone Bio Inc executives and independent directors trade stock every 103 days with the average trade being worth of $54,654. The most recent stock trade was executed by Andrew R Allen on 15 May 2024, trading 24,263 units of GRTS stock currently worth $18,197.

What does Gritstone Bio Inc do?

gritstone oncology is a cancer immunotherapy company developing next-generation personalized cancer therapeutics. gritstone brings together distinguished scientific founders, an experienced and diverse management team, a seasoned and successful board of directors, and very deep financial backing to tackle fundamental challenges at the intersection of cancer biology, immunology, and immunotherapy design. the company’s initial goal is to identify and deploy therapeutic neo-antigens from individual patients’ tumors to develop novel treatments for lung cancer. gritstone oncology is headquartered in the san francisco bay area with certain key functions located in cambridge, ma. gritstone oncology launched in october 2015 with a series a financing of $102 million.

Gritstone Bio Inc executives and stock owners

Gritstone Bio Inc executives and other stock owners filed with the SEC include:

• Andrew Allen,
  President, Chief Executive Officer, Director
• Jean-Marc Bellemin,
  Chief Financial Officer, Executive Vice President
• Raphael Rousseau,
  Executive Vice President, Chief Medical Officer
• Karin Jooss,
  Executive Vice President - Research, Chief Scientific Officer
• Roman Yelensky,
  Executive Vice President, Chief Technology Officer
• Dr. Andrew R. Allen BCh, BM, M.D., MA, MRCP, Ph.D.,
  Co-Founder, Pres, CEO & Director
• Erin E. Jones M.S.,
  Chief Operating Officer
• Steve Krognes,
  Independent Director
• Thomas Woiwode,
  Independent Director
• Richard Heyman,
  Independent Director
• Judith Li,
  Independent Director
• Nicholas Simon,
  Independent Director
• Elaine Jones,
  Chairman of the Board
• Vijay Yabannavar,
  Executive Vice President, Manufacturing and Technical Operations
• Erin Jones,
  Executive Vice President, Global Head of Regulatory Affairs and Quality Assurance
• Matthew Hawryluk,
  Executive Vice President, Chief Business Officer
• Alan C. Mendelson J.D.,
  Sec.
• Dr. Karin Jooss,
  Head of R&D
• Dr. Matthew Hawryluk,
  Exec. VP & Chief Bus. Officer
• Prof. Raphael F. Rousseau M.D., Ph.D.,
  Exec. VP & Chief Medical Officer
• Stacy Proctor,
  Sr. VP & Head of People
• Rahsaan W. Thompson J.D.,
  Exec. VP & Gen. Counsel
• James Cho,
  Chief Accounting Officer
• Vassiliki Economides,
  Exec. VP & CFO
• Stephen W Webster,
  
• Group, Llc Green Jeremy Red...,
  
• Venture Capital V, L.P.Vers...,
  
• Peter Svennilson,
  Director
• Group Ii, Lp Column Group I...,
  
• Lifesciences Iii, L.P.Claru...,
  
• Rahsaan Thompson,
  EVP and General Counsel
• Shefali Agarwal,
  
• Clare Fisher,
  
• Naiyer Rizvi,
  
• Lawrence Corey,
  
• James Cho,
  SVP, CHIEF ACCOUNTING OFFICER
• Vassiliki Economides,
  EVP, CHIEF FINANCIAL OFFICER